Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

Becton Dickinson and Co / Equity Bottom-Up

<ul>
<li>Ruling on Ethylene Oxide in favor of Sotera is a positive for all the medical devices companies including <a href="https://www.smartkarma.com/entities/becton-dickinson-and-co" target="_blank" data-smartkarma-citation="entities:13061:1" rel="noopener">Becton Dickinson and Co (BDX US)</a>, who have EO sterilization facilities.  </li>
<li>In FY22, BD reported strong base business, which grew 6.9% y/y on reported basis. On currency-neutral basis, base business increased 9.4% y/y in FY22, accelerated from 8.1% in FY21.</li>
<li>FY22 marks 51st consecutive year of dividend increase for BD, which makes it one of the leading dividend yield stocks. Currently, the stock has a dividend yield of 1.53%.</li>
</ul>


Ruling on Ethylene Oxide in favor of Sotera is a positive for all the medical devices companies including Becton Dickinson and Co (BDX US), who have EO sterilization facilities.  
In FY22, BD reported strong base business, which grew 6.9% y/y on reported basis. On currency-neutral basis, base business increased 9.4% y/y in FY22, accelerated from 8.1% in FY21.
FY22 marks 51st consecutive year of dividend increase for BD, which makes it one of the leading dividend yield stocks. Currently, the stock has a dividend yield of 1.53%.


Becton Dickinson and Co (BDX US): EO Ruling Is Positive; Strong Base Business to Drive Growth Ahead

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>We write about one stock each from the large, mid and small cap portfolios, briefly giving the reasons behind their the innovation scores and inclusion in the portfolio.  </li>
<li>The three companies are <a href="https://www.smartkarma.com/entities/johnson-johnson-831a1ab9-b291-4564-99b0-dc7f8d2b8175" target="_blank" data-smartkarma-citation="entities:26818:1" rel="noopener">Johnson &amp; Johnson (JNJ UN)</a> , <a href="https://www.smartkarma.com/entities/mondelez-international-inc" target="_blank" data-smartkarma-citation="entities:8111:1" rel="noopener">Mondelez International (MDLZ US)</a> and <a href="https://www.smartkarma.com/entities/qorvo-inc" target="_blank" data-smartkarma-citation="entities:11965:1" rel="noopener">Qorvo Inc (QRVO US), which have the highest weighting in each portfolio</a>
</li>
<li>For the week the large cap portfolio was up 1.2%, the midcap was up 1.4% and the small cap was up 0.9%, all in US$ terms.  </li>
</ul>


We write about one stock each from the large, mid and small cap portfolios, briefly giving the reasons behind their the innovation scores and inclusion in the portfolio.  
The three companies are Johnson &amp; Johnson (JNJ UN) , Mondelez International (MDLZ US) and Qorvo Inc (QRVO US), which have the highest weighting in each portfolio

For the week the large cap portfolio was up 1.2%, the midcap was up 1.4% and the small cap was up 0.9%, all in US$ terms.  


How the Portfolios Did for the First Week

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market share gains.</li><li>Thermo Fisher strengthened its market position during this quarter as it advanced its industry-leading Thermo Scientific Orbitrap portfolio and launched the Orbitrap Ascend Tribrid mass spectrometer during the International Mass Spectrometry Conference.</li><li>We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.</li></ul>

Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market share gains.Thermo Fisher strengthened its market position during this quarter as it advanced its industry-leading Thermo Scientific Orbitrap portfolio and launched the Orbitrap Ascend Tribrid mass spectrometer during the International Mass Spectrometry Conference.We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.

Thermo Fisher Scientific: New Technology For Cell Culture Harvesting & Other Drivers

<ul><li>Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.</li><li>Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.</li><li>We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.</li></ul>

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust.Excellent growth has been viewed over every business, highlighted by its pharma services and bioproduction businesses.We provide the stock of Thermo Fisher with a ‘Hold’ rating with a revision in the target price.

Thermo Fisher Scientific: New Product Launches & Other Drivers

Equity Capital Markets

Thermo Fisher Scientific Inc / Equity Capital Markets

<ul><li>Thermo Fisher Scientific had a strong start to 2022, with its core business performing well.</li><li>Thermo Fisher was able to gain market share and deliver a strong execution.</li><li>The company viewed a strong growth in the healthcare market channel, transparent diagnostics, and clinical diagnostics in the core business.</li></ul>

Thermo Fisher Scientific had a strong start to 2022, with its core business performing well.Thermo Fisher was able to gain market share and deliver a strong execution.The company viewed a strong growth in the healthcare market channel, transparent diagnostics, and clinical diagnostics in the core business.

Thermo Fisher Scientific Inc: New Product Launches & Other Key Drivers

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific (TMO UN)

Becton Dickinson and Co (BDX US): EO Ruling Is Positive; Strong Base Business to Drive Growth Ahead

Recent EO ruling is positive for BD. Base business momentum, new launches targeting higher-impact and higher-growth markets, and tuck-in M&A should...

Tina Banerjee

How the Portfolios Did for the First Week

We assess how the three portfolios did for the first week and discuss about one stock each from the large, mid and small cap portfolios, briefly...

Pyari Menon

Thermo Fisher Scientific: New Technology For Cell Culture Harvesting & Other Drivers

Thermo Fisher Scientific had a positive quarterly result as it surpassed Wall Street expectations on all counts and continued to drive market...

Baptista Research

Thermo Fisher Scientific: New Product Launches & Other Drivers

Thermo Fisher had a good quarter and delivered an all-around beat as a result of the fact that its core business has been robust. Excellent growth...

Baptista Research

Thermo Fisher Scientific Inc: New Product Launches & Other Key Drivers

Thermo Fisher Scientific had a strong start to 2022, with its core business performing well. Thermo Fisher was able to gain market share and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)